A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

Inclusion Criteria: * Diagnosis of diabetes mellitus (Type 1 or Type 2) * Macular thickening secondary to diabetic macular edema (DME) involving the center of the macula * Decreased visual acuity attributable primarily to DME * Ability and willingness to provide written informed consent and to comply with the study protocol * Willingness to allow Aqueous Humor collection * For women of childbearing potential: agreement to remain abstinent or use at least one highly effective contraceptive method that results in a failure rate of \<1% per year during the treatment period and for at least 12 weeks after the final dose of study treatment Exclusion Criteria: * Hemoglobin A1c (HbA1c) of greater than (\>) 12% * Uncontrolled blood pressure, defined as a systolic value greater than (\>)180 millimeters of mercury (mmHg) and/or a diastolic value \>100 mmHg while a patient is at rest * Currently pregnant or breastfeeding, or intend to become pregnant during the study * Prior treatment with panretinal photocoagulation or macular laser to the study eye * Any intraocular or periocular corticosteroid treatment within the past 16 weeks prior to Day 1 to the study eye * Prior Iluvien or Retisert implants within 3 years prior to Day 1 to the study eye * Prior or concomitant treatment with anti-VEGF therapy within 8 weeks prior to Day 1 to the study eye; Vabysmo\^TM within 16 weeks prior to Day 1, prior Beovu® is not permitted * Prior administration of IVT brolucizumab (Beovu®): ever; vamiki…